Trial Profile
A study evaluating reversible nature of cardiovascular autonomic responses to autonomic challenge in patients with relapsing remitting multiple sclerosis (RRMS) during Fingolimod therapy and after Fingolimod discontinuation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 25 Jul 2017 New trial record
- 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology
- 27 Jun 2017 Results (n=10) presented at the 3rd Congress of the European Academy of Neurology